p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells

Citation
Mc. Mingari et al., p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells, IMMUNOL REV, 181, 2001, pp. 260-268
Citations number
39
Categorie Soggetti
Immunology
Journal title
IMMUNOLOGICAL REVIEWS
ISSN journal
01052896 → ACNP
Volume
181
Year of publication
2001
Pages
260 - 268
Database
ISI
SICI code
0105-2896(200106)181:<260:PACTSR>2.0.ZU;2-B
Abstract
Inhibitory receptors originally identified in natural killer (NK) cells hav e also been detected in other leukocyte types, thus suggesting that they ma y play a more general role in the control of leukocyte function. Here we re port data on p75/adhesion receptor molecule I (AIRM1), a surface inhibitory receptor of the sialoadhesin family originally identified in NK cells that is also expressed by normal and leukemic myeloid cells. Given the homology between p75/AIRM1 and CD33, we also reanalyzed CD33, a major myeloid marke r of still unknown function. We discuss recent data indicating that engagem ent of p75/AIRM1 or CD33 sharply inhibits the in vitro proliferation/differ entiation of CD34(+) myeloid precursors induced by stem cell factor and gra nulocyte macrophage colony-stimulating factor. importantly, a similar in vi tro inhibitory effect occurs in monocyte/macrophages as well as in chronic or acute myeloid leukemias. While CD33 appears to act via the induction of apoptosis, p75/AIRM1 blocks cell proliferation but does not appear to induc e apoptosis. A synergistic effect in the induction of apoptosis has also be en documented between antibodies specific for CD33 and the chemotherapic ag ent etoposide. Taken together, the use of appropriate ligands against CD33 or p75/AIRM1 may represent a new therapeutic tool for treatment of myeloid leukemias or diseases characterized by overwhelming macrophage activation.